Antifungal agents: an overview. Part II. (Q40449449)

20 September 2017

1 reference

title

Antifungal agents: an overview. Part II. (English)

1 reference

20 September 2017

Gupta AK

1

1 reference

20 September 2017

Sauder DN

series ordinal

2

1 reference

20 September 2017

Shear NH

series ordinal

3

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 June 1994

1 reference

Journal of the American Academy of Dermatology

20 September 2017

1 reference

20 September 2017

30

1 reference

20 September 2017

911-33; quiz 934-6

1 reference

20 September 2017

6

1 reference

New oral treatments for dermatophytosis

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of chronic dermatophytosis and chronic oral candidosis with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

1 reference

7 January 2021

A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Hepatic reactions associated with ketoconazole in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Ketoconazole-induced fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Hepatic reactions during ketoconazole treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

New drugs for systemic fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole in Antifungal Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole: pharmacologic studies in animals and humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Pharmacokinetic profile of orally administered itraconazole in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

New antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole pharmacokinetics in patients with renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Orally administered ketoconazole: route of delivery to the human stratum corneum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Griseofulvin levels in stratum corneum. Study after oral administration in man

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Hepatic injury associated with itraconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Role of animal and human pharmacology in antifungal drug design

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

The new generation of antifungal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Adrenal response to corticotropin during therapy with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Adverse events associated with itraconazole in 189 patients on chronic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

An evaluation of itraconazole in the management of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Potentiation of action of warfarin by itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Digoxin toxicity associated with itraconazole therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole-Digoxin Interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Cyclosporine and itraconazole interaction in heart and lung transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Time course of cyclosporin/itraconazole interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole and cyclosporin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Adherence of dermatophyte microconidia and arthroconidia to human keratinocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

In vitro studies with R 51,211 (itraconazole)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A comparison of the efficacy of itraconazole, amphotericin B and 5-fluorocytosine in the treatment of Aspergillus fumigatus endocarditis in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole Compared with Griseofulvin in the Treatment of Tinea corporis/cruris and Tinea pedis/manus: An Interpretation of the Clinical Results of all Completed Double-Blind Studies with Respect to the Pharmacokinetic Profile

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole in the treatment of dermatophytoses: a comparison of two daily dosages

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole in the treatment of tinea corporis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole in the management of chronic dermatophytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea pedis and tinea manuum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole in the treatment of superficial mycoses--a double-blind study vs. placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of dermatophytoses and pityriasis versicolor with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole in pityriasis versicolor

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole in the treatment of tinea capitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Efficacy and safety of itraconazole in the long-term treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Onychomycosis Treated with Itraconazole or Griseofulvin Alone with and without a Topical Antimycotic or Keratolytic Agent

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of oral candidosis with itraconazole: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Tolerance to and efficacy of itraconazole in treatment of systemic mycoses: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Determination of griseofulvin in skin, plasma, and sweat.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Role of Sweat in Accumulation of Orally Administered Griseofulvin in Skin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole in opportunistic mycoses: cryptococcosis and aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of chromoblastomycosis with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of chromomycosis with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A case of chromoblastomycosis responding to treatment with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of invasive aspergillosis with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole therapy in aspergillosis: study in 49 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole in the treatment of paracoccidioidomycosis: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole treatment of phaeohyphomycosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Cutaneous leishmaniasis. Treatment with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Acute pyogenic Pseudallescheria boydii foot infection sequentially treated with miconazole and itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Azole antifungal agents: emphasis on new triazoles

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Drug interactions with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Effect of oral antacid administration on the pharmacokinetics of oral fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Influence of food on the pharmacokinetics of ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole in the treatment of fungal infections associated with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Sputum levels of fluconazole in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole levels in human epidermis and blister fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Clinical pharmacokinetics of fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Mechanisms of action of the antimycotic imidazoles

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Cytochemical and Biochemical Studies of Yeasts After In Vitro Exposure to Miconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Effect of imidazole antifungals on the development of germ tubes by strains of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole and testosterone: in vivo and in vitro studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

The influence of gastric acidity on the bio-availability of ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Pharmacokinetics of ketoconazole-antipyrine interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Interaction of Ketoconazole with Rifampin and Isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Pharmacokinetic study of the interaction between rifampicin and ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Interaction between fluconazole and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole in the treatment of candidal prosthetic valve endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole and phenytoin: a predictable interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Interaction of fluconazole and cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

INTERACTION OF FLUCONAZOLE WITH CYCLOSPORIN

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Interaction of fluconazole with cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Antifungal susceptibility tests

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Testing of organisms for susceptibility to triazoles: is it justified?

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of cryptococcal meningitis in mice with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Comparison of the in vitro and in vivo activity of the bis-triazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Comparison of fluconazole and SDZ89-485 for therapy of experimental murine coccidioidomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea corporis/cruris and cutaneous candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Therapy with fluconazole for tinea corporis, tinea cruris, and tinea pedis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea pedis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of kerion with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Tinea versicolor treated with fluconazole shampoo

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole in the management of patients with chronic mucocutaneous candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A comparison of fluconazole and ketoconazole in the oral treatment of vaginal candidiasis; report of a double-blind multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A comparison of single-dose oral fluconazole with 3-day intravaginal clotrimazole in the treatment of vaginal candidiasis. Report of an international multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of vaginal candidiasis with a single oral dose of fluconazole. Multicentre Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of candidal leukoplakia with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole in the treatment of Candida-associated denture stomatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole therapy in an underweight infant

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of systemic yeast infection with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole in renal candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole and candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Amphotericin-resistant invasive hepatosplenic candidiasis controlled by fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A clinical study of fluconazole for the treatment of deep mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Synthesis and structure-activity correlations within allylamine antimycotics

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

In vitro activity of naftifine, a new antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

In vivo antimycotic activity of naftifine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Antifungal activity of the allylamine derivative terbinafine in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Pharmacology of the allylamines

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Clinical pharmacokinetics of terbinafine (Lamisil).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Determination of terbinafine in nail samples during systemic treatment for onychomycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Pharmacokinetics of terbinafine in the nail

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Terbinafine: An oral and topical antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Terbinafine: mode of action and properties of the squalene epoxidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Clinical singgnificance of interactions with antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Special features of the clinical use of oral terbinafine in the treatment of fungal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Clinical efficacy and tolerability of terbinafine (Lamisil)--a new topical and systemic fungicidal drug for treatment of dermatomycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Hepatitis associated with terbinafine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Loss of taste and terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Loss of taste and terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Loss of taste and terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of cutaneous sporotrichosis with terbinafine.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Activity of terbinafine in experimental fungal infections of laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Azoles, a48 llylamines and drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

In vitro activity of terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A comparative study of terbinafine versus griseofulvin in 'dry-type' dermatophyte infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. Results of placebo-controlled, double-blind, multicenter trials

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1- and 4-week treatment regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of onychomycosis with terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Short term treatment of dermatophyte onychomycosis with terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A randomized treatment duration-finding study of terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Single dose treatment of fungal nail disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Terbinafine: efficacy and safety in the treatment of dermatophytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Nail is produced by the normal nail bed: a controversy resolved

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Continuous formation of nail along the bed

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Clinical relevance of the antibacterial activity of terbinafine: a contralateral comparison between 1% terbinafine cream and 0.1% gentamicin sulphate cream in pyoderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

An investigation of the pharmacokinetics of topical terbinafine (LamisilR) 1% cream

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Double-blind comparison of naftifine cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Morpholine antifungals and their mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

A clinical double-blind trial comparing amorolfine cream 0.5% (RO-14-4767) with bifonazole cream 1% in the treatment of dermatomycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Percutaneous absorption of amorolfine following a single topical application of an amorolfine cream formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Preclinical data and mode of action of amorolfine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Mode of action of morpholine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Morphological changes associated with growth inhibition of Trichophyton mentagrophytes by amorolfine.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Dose-finding study of amorolfine cream (0.125%, 0.25% and 0.5%) in the treatment of dermatomycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Experience with amorolfine in the treatment of dermatomycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Double-blind comparison of amorolfine and bifonazole in the treatment of dermatomycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Absorption of amorolfine through human nail

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Tioconazole nail solution--an open study of its efficacy in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Loceryl nail lacquer--realization of a new galenical approach to onychomycosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Percutaneous Absorption. On the Relevance of in Vitro Data

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychomycosis: comparison of two nail lacquer formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2894%2970112-1

7 January 2021

10.1016/S0190-9622(94)70112-1

Identifiers

DOI

1 reference

20 September 2017

1 reference